Revance Therapeutics (RVNC) Tops Q3 EPS by 20c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.81), $0.20 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $90 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target
• Hermès can regain momentum despite China weakness, Jefferies says